CD103

Rb

Artikelnummer:CD297-H
Menge:
Technische Daten
Kontrolle:Human colon tissue
Zelluläre Lokalisation:Membranous
Vorbehandlung:ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Immunogen:Synthetic peptide of human CD103
Ig Unterklasse:IgG
Spezies:Rabbit
Status:In Vitro Diagnostic Use (IVD)
Change(s) made:Complete revision
Synonyme:alpha-E1, alpha-M290, aM290, Antigen CD103, CD 103, CD103, CD103 antigen, HML 1 antigen, HML1 antigen, Human mucosal lymphocyte antigen 1, Human mucosal lymphocyte antigen 1, alpha subunit, Huminae, Integrin alpha E heavy chain, Integrin alpha E light chain, Integrin alpha E, epithelial-associated, Integrin alpha E1, Integrin alpha IEL, Integrin alpha M290, Integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1, alpha polypeptide), Integrin, alpha E, ITGAE, MGC141996, MGC183601, Mucosal lymphocyte 1 antigen, Mucosal lymphocyte antigen 1.
Verfügbar in folgenden Ländern:worldwide
Beschreibung

CD103, also known as Integrin alpha E or ITGAE, is a membrane-associated protein that belongs to the family of integrins. It functions in cell adhesion, migration, cell signaling and localization of lymphocytes in epithelial tissues. CD103 is expressed on T-lymphocytes in gastro-intestinal tract, bronchoalveolar fluids and allograft tissues. Immune cells in spleen or peripheral lymph nodes poorly express CD103. Antibody CD103 may be helpful in detection of hairy cell leukemia and HCL variants, which are CD103 positive. Most other hematologic malignancies are negative for CD103.

Literatur

[1] Anz D, Mueller W, Golic M et al. (2011): CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer. 129(10):2417-26.
[2] Uss E, Rowshani AT, Hooibrink B et al. (2006): CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J Immunol. 177(5):2775-83.
[3] Venkataraman G, Aguhar C, Kreitman RJ et al. (2011): Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. 136(4):625-30.

Kontakt